Thomas Schmitt täze makala döretdi
2 ýyl - Terjime

Effects of Glucagon-Like Peptide-1 Receptor Agonists on Diabetic Cardiomyopathy | #glp-1

Effects of Glucagon-Like Peptide-1 Receptor Agonists on Diabetic Cardiomyopathy

Effects of Glucagon-Like Peptide-1 Receptor Agonists on Diabetic Cardiomyopathy

The incidence and prevalence of diabetes are increasing year by year globally, and patients with diabetes are at increased risk of cardiovascular disease and heart failure. Diabetic cardiomyopathy (DCM) refers to the presence of abnormal myocardial structure and performance in the absence